Myofibroblast

Endeavor BioMedicines Doses First Patient in Phase 2 Clinical Trial of Taladegib (ENV-101) for Idiopathic Pulmonary Fibrosis; Appoints Chief Medical Officer

Retrieved on: 
Wednesday, September 22, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Publication, Degenerative disease, Idiopathic pulmonary fibrosis, Patient, NDA, University of Illinois at Chicago College of Dentistry, FVC, Cancer, Precision medicine, Pathology, Siberian State Medical University, Endeavour, Hedgehog, FEV1, CEO, Merck, IPF, University, Growth, Tufts University School of Medicine, Pharmacology, Apoptosis, Entrepreneurship, Disease, Johns Hopkins University, HIV disease progression rates, Technology, Drug development, Myofibroblast, Safety, Fibrosis, Pulmonology, Lung, Pharmaceutical industry, Taladegib (ENV-101) for the Treatment of IPF, Endeavor BioMedicines, TALADEGIB (ENV-101) FOR THE TREATMENT OF IPF, ENDEAVOR BIOMEDICINES

Endeavor also announced today that Srikanth Pendyala, M.D., has been appointed as the companys first Chief Medical Officer.

Key Points: 
  • Endeavor also announced today that Srikanth Pendyala, M.D., has been appointed as the companys first Chief Medical Officer.
  • Hood added, We are also pleased to welcome Srikanth Pendyala as our chief medical officer.
  • Endeavors forward-thinking approach to precision therapies used to treat pulmonary disease and cancer has already exhibited immense potential since the company launched, said Srikanth Pendyala, M.D., Chief Medical Officer, Endeavor BioMedicines.
  • Endeavor BioMedicines is a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis.

Blade Therapeutics Announces Positive Data from Preclinical Drug-Drug Interaction Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis (IPF)

Retrieved on: 
Monday, September 20, 2021
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Food, Therapy, RATS, Clinical trial, Neurodegeneration, Mortality, Pharmacokinetics, CYP450, Lung, Fibrosis, Lysophosphatidic acid, Interstitial lung disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Galapagos NV, FDA, Patient, Protein aggregation, AUC, Disease, Kidney, NASH, CEO, Matrix, Medicine, IPF, Company, LPA, Trial of the century, Risk, Liver, HIV disease progression rates, Male, Myofibroblast, Autotaxin, Safety, Enzyme, Institute of Liver and Biliary Sciences, Boehringer Ingelheim, Plasma, Pharmaceutical industry

Nintedanib, a medicine from Boehringer Ingelheim, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of IPF.

Key Points: 
  • Nintedanib, a medicine from Boehringer Ingelheim, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of IPF.
  • We believe that these are important data that help inform our step-wise approach to advance the clinical development program for cudetaxestat, said Wendye Robbins, M.D., president and CEO of Blade.
  • In the preclinical study, 18 male rats received daily oral administration with nintedanib only during study days one through four.
  • Blade plans to further analyze data from this study and intends to submit study data for potential publication in a peer-reviewed scientific journal.

Simon Sturge Joins Mediar Therapeutics as Executive Chairman

Retrieved on: 
Wednesday, September 15, 2021
Professional Services, Health, Venture Capital, General Health, Pharmaceutical, Biotechnology, Pathology, Therapy, Cell, Nemesis, CEO, Drug development, Myofibroblast, Silence Therapeutics, Fibrosis, Disease, Cirrhosis, Hospital, Boehringer Ingelheim, Massachusetts General Hospital, Mass, Sale, Pharmaceutical industry

Mediar Therapeutics today announced Simon Sturge has joined the firm as executive chairman.

Key Points: 
  • Mediar Therapeutics today announced Simon Sturge has joined the firm as executive chairman.
  • We are thrilled to welcome Simon to Mediar as we move towards bringing our breakthrough treatments for fibrosis to the clinic, said Meredith Fisher, Ph.D., founding CEO of Mediar and a partner at Mass General Brigham Ventures.
  • Im excited to help lead Mediar into its next stage of development, said Sturge.
  • Mediar Therapeutics is a discovery stage biotechnology company developing treatments to halt, or even reverse, fibrosis.

Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Retrieved on: 
Monday, September 13, 2021
Idiopathic pulmonary fibrosis, U.S. Securities and Exchange Commission, Liver transplantation, Security (finance), CEO, Cirrhosis, Myofibroblast, Child–Pugh score, Patient, TGF, LOXL2, Private Securities Litigation Reform Act, Large-cell lung carcinoma, Hepatocellular carcinoma, Collagen, Fibrosis, Disease, Annual report, Safety, Child, NASDAQ, Ruxolitinib, Pharmacokinetics, IPF, NSCLC, GLOBE, Liver failure, SEC, Liver, Cancer, Pharmaceutical industry, Dietary supplement

This trial marks the initiation of Galectos clinical program for GB1211 in liver cirrhosis.

Key Points: 
  • This trial marks the initiation of Galectos clinical program for GB1211 in liver cirrhosis.
  • The trial will randomize liver cirrhosis patients of any etiology and evaluate the impact of GB1211 on liver fibrosis and liver function.
  • Galectin-3 is elevated in cirrhosis patients and is a prognostic biomarker of hepatocellular carcinoma, a known complication of liver cirrhosis.
  • There are no approved disease modifying therapies and liver transplantation remains the sole option for late stage liver cirrhosis.

Blade Therapeutics Announces FDA Activation of IND Application to Investigate Cudetaxestat, a Non-Competitive Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (IPF)

Retrieved on: 
Wednesday, August 25, 2021
Biotechnology, Health, Clinical Trials, Other Health, Company, Myofibroblast, Neurodegeneration, Liver, Fibrosis, Autotaxin, Lysophosphatidic acid, Matrix, Pharmacokinetics, Protein aggregation, IPF, Food, Kidney, Therapy, Fatty liver disease, Investment, CYP450, Clinical trial, Institute of Liver and Biliary Sciences, Mortality, IND, Safety, Interstitial lung disease, Disease, Enzyme, LPA, Patient, HIV disease progression rates, CEO, Lung, Bristol Myers Squibb, FDA, NASH, Biomedical Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

The FDA informed Blade that it has completed its 30-day safety review of the IND and indicated that the Company may proceed with its proposed clinical investigation for IPF.

Key Points: 
  • The FDA informed Blade that it has completed its 30-day safety review of the IND and indicated that the Company may proceed with its proposed clinical investigation for IPF.
  • This study in healthy subjects is projected to start in the second half of 2021 and complete in the first half of 2022.
  • We are focused on advancing cudetaxestat in pursuit of our mission to bring life-changing treatments to patients with intractable diseases.
  • In addition, autotaxin levels correlate with fibrosis severity in various liver diseases (e.g., nonalcoholic fatty liver disease / nonalcoholic steatohepatitis (NASH)).

Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOME™ Technology

Retrieved on: 
Wednesday, April 8, 2020
Myofibroblast

Inhaled LAMELLASOME treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.

Key Points: 
  • Inhaled LAMELLASOME treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.
  • Lamellar Biomedical Limited (Lamellar), is an innovative biotechnology company, developing our proprietary LAMELLASOME based therapies to transform the treatment of complex and rare lung disorders.
  • Lamellasome modifies the actions of a number of key proinflammatory and profibrotic mediators, including TGF-, preventing fibroblast to myofibroblast transition.
  • These properties provide low immunogenicity and excellent safety, LAMELLASOME vesicles have been shown to have inherent pulmonary protective effects.

Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOME™ Technology

Retrieved on: 
Wednesday, April 8, 2020
Myofibroblast

Inhaled LAMELLASOME treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.

Key Points: 
  • Inhaled LAMELLASOME treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.
  • Lamellar Biomedical Limited (Lamellar), is an innovative biotechnology company, developing our proprietary LAMELLASOME based therapies to transform the treatment of complex and rare lung disorders.
  • Lamellasome modifies the actions of a number of key proinflammatory and profibrotic mediators, including TGF-, preventing fibroblast to myofibroblast transition.
  • These properties provide low immunogenicity and excellent safety, LAMELLASOME vesicles have been shown to have inherent pulmonary protective effects.

Prometic presents new PBI-4050 and Ryplazim™ (plasminogen) data on lung fibrosis at the 2019 ATS Conference

Retrieved on: 
Wednesday, May 22, 2019
Branches of biology, Medicine, Biology, Myofibroblast, IPF, Pulmonary fibrosis, Fibrosis, Idiopathic pulmonary fibrosis

Importantly, PBI-4050 has now been demonstrated to reduce fibrosis in two models of pulmonary fibrosis, commented Dr. Lyne Gagnon, Vice President of Preclinical R&D at Prometic.

Key Points: 
  • Importantly, PBI-4050 has now been demonstrated to reduce fibrosis in two models of pulmonary fibrosis, commented Dr. Lyne Gagnon, Vice President of Preclinical R&D at Prometic.
  • We are planning a randomized, placebo-controlled, phase 2 clinical study of PBI-4050 in patients with IPF to be initiated later in the year.
  • In lung fibroblasts cultured from IPF patients, PBI-4050 inhibited myofibroblast activation and returned mRNA expression of profibrotic and extracellular matrix markers to control levels.
  • Our lead drug candidate, PBI-4050, is expected to enter Phase 3 clinical studies for the treatment of Alstrm Syndrome in 2019.